MA47415A - INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES - Google Patents

INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES

Info

Publication number
MA47415A
MA47415A MA047415A MA47415A MA47415A MA 47415 A MA47415 A MA 47415A MA 047415 A MA047415 A MA 047415A MA 47415 A MA47415 A MA 47415A MA 47415 A MA47415 A MA 47415A
Authority
MA
Morocco
Prior art keywords
inhibition
platelet aggregation
human gpvi
gpvi antibodies
antibodies
Prior art date
Application number
MA047415A
Other languages
French (fr)
Inventor
Gilles Avenard
Philippe Billiald
Martine Jandrot-Perrus
Original Assignee
Acticor Biotech
Inserm Institut National De La Sante Et De La Recherche Scient
Univ Paris Diderot Paris 7
Univ Paris Sud 11
Univ Paris Xiii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acticor Biotech, Inserm Institut National De La Sante Et De La Recherche Scient, Univ Paris Diderot Paris 7, Univ Paris Sud 11, Univ Paris Xiii filed Critical Acticor Biotech
Publication of MA47415A publication Critical patent/MA47415A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
MA047415A 2017-02-03 2018-02-02 INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES MA47415A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17154658 2017-02-03

Publications (1)

Publication Number Publication Date
MA47415A true MA47415A (en) 2019-12-11

Family

ID=57963133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047415A MA47415A (en) 2017-02-03 2018-02-02 INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES

Country Status (13)

Country Link
US (2) US11692033B2 (en)
EP (1) EP3577136A1 (en)
JP (2) JP7360945B2 (en)
KR (2) KR102633644B1 (en)
AU (2) AU2018214222C1 (en)
BR (1) BR112019016065A8 (en)
CA (1) CA3051169A1 (en)
IL (1) IL268299A (en)
MA (1) MA47415A (en)
MX (1) MX2019009137A (en)
SG (1) SG11201906530TA (en)
TW (2) TW202339799A (en)
WO (1) WO2018141909A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250026A1 (en) * 2020-06-08 2021-12-16 Acticor Biotech Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
WO2023036815A1 (en) * 2021-09-07 2023-03-16 Etablissement Francais Du Sang Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023156683A1 (en) * 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IE69054B1 (en) 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
DE3903581A1 (en) 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh FABRIC PLASMINOGEN ACTIVATOR DERIVATIVE
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DK0643772T3 (en) 1992-06-03 1998-02-02 Genentech Inc Glycosylation variants of tissue plasminogen activator with improved therapeutic properties
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
CN1964990B (en) 2004-04-29 2012-12-12 大冢制药株式会社 Antibodies specific for glycoprotein VI and methods of producing these antibodies
CA2606450A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006117910A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP5843783B2 (en) 2009-12-18 2016-01-13 サノフイ Novel antagonist antibody against GPVI, Fab fragment of the antibody and use thereof
JP5989096B2 (en) 2011-09-01 2016-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-human XCR1 antibody
ES2823998T3 (en) 2011-09-08 2021-05-11 Inst Nat Sante Rech Med New mutated tissue plasminogen activators and their uses
IL257323B2 (en) 2015-08-05 2024-01-01 Acticor Biotech Novel anti-human gpvi antibodies and uses thereof

Also Published As

Publication number Publication date
BR112019016065A8 (en) 2022-10-18
CA3051169A1 (en) 2018-08-09
AU2018214222B2 (en) 2021-01-28
KR102633644B1 (en) 2024-02-05
KR20190121767A (en) 2019-10-28
WO2018141909A1 (en) 2018-08-09
AU2018214222A1 (en) 2019-08-01
AU2021202612B2 (en) 2024-03-14
RU2019127768A3 (en) 2021-05-28
BR112019016065A2 (en) 2020-05-26
US20190367608A1 (en) 2019-12-05
CN110494447A (en) 2019-11-22
TW201839009A (en) 2018-11-01
US20230391869A1 (en) 2023-12-07
JP2023109987A (en) 2023-08-08
KR20240046168A (en) 2024-04-08
JP7360945B2 (en) 2023-10-13
AU2018214222C1 (en) 2021-08-05
JP2020507317A (en) 2020-03-12
SG11201906530TA (en) 2019-08-27
AU2021202612A1 (en) 2021-05-27
TWI810173B (en) 2023-08-01
IL268299A (en) 2019-09-26
MX2019009137A (en) 2019-12-19
RU2019127768A (en) 2021-03-03
US11692033B2 (en) 2023-07-04
EP3577136A1 (en) 2019-12-11
TW202339799A (en) 2023-10-16

Similar Documents

Publication Publication Date Title
MA45539A (en) DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS
MA43956A (en) CONSTRUCTIONS OF BISPECIFIC ANTIBODIES OF ENGAGEMENT WITH T-CELLS
MA47208A (en) CANCER TREATMENT METHODS USING ANTI-PD-1 ANTIBODIES
MA42924A (en) OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
MA52742A (en) BISPECIFIC ANTIBODIES DLL3-CD3
MA53434A (en) ANTI-TIGIT ANTIBODIES
MA50505A (en) 2 + 1 BISPECIFIC ANTIBODIES (CONTORSBODIES)
MA52884A (en) ANTI-IL-11 ANTIBODIES
MA55629A (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
MA43197A (en) BISPECIFIC ANTIBODY CONSTRUCTIONS FOR CDH3 AND CD3
MA49726A (en) FORMULATION OF ANTI-CGRP ANTIBODIES
MA45688A (en) COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS
MA51677A (en) CANCER TREATMENT METHODS USING ANTI-PD-1 ANTIBODIES
MA47604A (en) ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
MA53905A (en) TREM2 STABILIZING ANTIBODY
FR3022462B1 (en) ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY
MA46851A (en) NEW Fab FRAGMENT OF ANTI-HUMAN MUC1 ANTIBODIES
MA53831A (en) METHODS OF REDUCING THE AGGREGATION OF B-SPECIFIC ANTIBODIES
MA51337A (en) SPIRO EXO-AZA INHIBITORS OF MENIN-MLL INTERACTION
MA47415A (en) INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES
MA52152A (en) ANTIBODY
MA44236A (en) ANTI-TGFBETA ANTIBODY 2
MA49781A (en) DIRECT EXPRESSION OF ANTIBODIES
MA46431A (en) COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF TAU
MA52076A (en) ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES